CoChat

Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics

Sverdlov, Aaron L., Ngo, Doan T.M., Chan, Wai P.A., Chirkov, Yuliy Y., Gersh, Bernard J., McNeil, John J., Horowitz, John D. · 2012 · European Heart Journal
Cited by 35

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

AIMS: Aortic valve stenosis (AS) and its precursor, aortic valve sclerosis (ASc), occur frequently in Western populations. Investigations to retard the progression of AS using statins have been unsuccessful. Development of ASc in humans is associated with increased aortic valve backscatter (AVBS) and poor tissue nitric oxide (NO) responsiveness. In an animal model, ramipril retarded AS/ASc development. We have now set out to identify factors associated with the progression of ASc in humans. METHODS AND RESULTS: At baseline and after 4 years, 204 randomly selected subjects (age 63 ± 6 years at study entry) underwent echocardiography with the determination of AVBS values, measurements of platelet NO responsiveness, plasma asymmetric dimethylarginine concentrations, lipid profile, high-sensitivity-C-reactive protein, routine biochemistry, and 25-hydroxy-vitamin D levels. During the study period, 68% of subjects had detectable AVBS progression. On multivariate analysis, higher calcium concentrations (β = 0.22; P = 0.004), poor platelet NO responsiveness (β = 0.18; P = 0.018), and increased arterial stiffness (β = 0.15; P = 0.044) were independent predictors of disease progression. The use of angiotensin-converting enzyme-inhibitors/angiotensin II receptor blockers (ACE-I/ARB) predicted the lack of disease progression (assessed categorically) in the overall cohort and in those without ASc at baseline (n = 159) (β = 0.8; P = 0.025 and β = 1.3; P = 0.001, respectively). No conventional coronary risk factors were associated with disease progression. CONCLUSION: This study of early aortic valve disease (i) demonstrates that disease progression occurs in the majority of the normal ageing population over a 4-year period; (ii) provides evidence of the importance of the NO signalling cascade in disease development and progression; and (iii) provides additional data linking ACE-I/ARB use with the retardation of ASc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehs171

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 35

Metadata

Authors
Sverdlov, A. L., Ngo, D. T. M., Chan, W. P. A., Chirkov, Y. Y., Gersh, B. J., McNeil, J. J., & Horowitz, J. D.
Venue
European Heart Journal
Published
2012-07-06
Volume
33
Issue
19
Pages
2419-2425
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2147500593
Cited by
35
References
9
FWCI
3.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. https://app.cochat.ai/papers/10.1093/eurheartj/ehs171
The paper
Sverdlov, A. L., Ngo, D. T. M., Chan, W. P. A., Chirkov, Y. Y., Gersh, B. J., McNeil, J. J., & Horowitz, J. D. (2012). Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. European Heart Journal. https://doi.org/10.1093/eurheartj/ehs171

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.